U.S. PCT Application Serial No.: 10/519,680 Docket No.: 263378US0PCT

## STATEMENT OF RELEVANCY

Re	port. Copies of	these references are	have been cited in the International Search being submitted herewith only when not ional Searching Authority.
			have been cited in the corresponding European nees is being submitted herewith.
		AC, AL-AAX being submitted her	are discussed in the specification. A copy of re with.
		are additio	nal prior art known to Applicant. A copy of rewith.

# STOP PCT ND TRADEMARK OFFICE

IN RE APPLICATION OF:

Claudio SOTO-JARA, et a

IN THE UNITED STATES P

SERIAL NO: 10/519,680

FILED:

January 7, 2005

FOR:

BETA-SHEET BREAKING PEPTIDES

GAU:

**EXAMINER:** 

ICO3 Rec'd PCT/PTO 22 MAR 2009

#### ENT UNDER 37 CFR 1.97 INFORMATION DISCLOSURE

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

#### REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

#### **RELATED CASES**

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

### CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

#### DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND. MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Surinder Sachar

Registration No. 34,423

Customer Number

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

Form PTO 1449 U.S. DEPARTMENT OF COMMERCE		ATTY DOCKET NO.	SERIAL NO.			
(Modified) PATENT AND TRADEMARK OFFICE			263378US0PCT	10/519,680		
			APPLICANT			
LIST OF RE	FERENCES CITED B	Y APPLICANT	Claudio SOTO-JARA, et al.			
			FILING DATE	GROUP		
			January 7, 2005			
		FO	REIGN PATENT DOCUMENTS			
<u> </u>						
	NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
A	A 01/34631	05/17/01	wo	NO		
	B 01/07473	02/01/01	wo	NO		
	C 96/39834	12/19/96	wo	NO		
	D 02/064734	08/22/02	wo	NO		
1 ~	•	1		1 1		
			Including Author, Title, Date, Pertine			
А	E of Amino Acids, I 1982					
Д	SOTO, Claudio et al. "Inhibition of Alzheimer's Amyloidosis by Peptides that Prevent beta-Sheet Conformation", Biochemica and Biophysical Research Communications", vol. 226, no.3, pages 672-680, XP002050229  1996					
Α	PERMANNE, Bridisease by treatr 2002	PERMANNE, Bruno et al. "Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide", The FASEB Journal, vol. 16, no. 8, pages 860, 862, XP002265906				
A	ADESSI, Celine	ADESSI, Celine et al. "Pharmacological Profiles of Peptide Drug Candidates for the Treatment of Alzheimer's Disease", The Journal of Biological Chemistry, vol. 278, no. 16, pages 13905-13911, XP002265907				
,	PERMANNE, Bri	PERMANNE, Bruno et al. "Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide", The FASEB Journal Express Article, no. 108411, pages 1-24, XP002237080				
A	SOTO, Claudio e	SOTO, Claudio et al. "Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy", Nature Medicine, vol. 4, no. 7, pages 822-826, XP000914747				
	PODUSLO, Jose Brain Barrier Per	PODUSLO, Joseph F. et al. "Beta-sheet Breaker Peptide Inhibitor of Alzheimer's Amyloidogenesis with Increased Blood- Brain Barrier Permeability and Resistance to Proteolytic Degradation in Plasma", Journal of Neurobiology, vol. 39, no.3, pages 371-382, XP009008758				
Д	SELKOE, Dennis J. "Alzheimer's Disease: Genotypes, Phenotype, and Treatments", Science, vol. 275, pages 630-631					
YANKNER, Bruce A. et al. "Beta-Amyloid and the Pathogenesis of Alzheimer's Disease", The New Eng AM Medicine, vol. 325, no. 26, pages 1849-1857				er's Disease", The New England Journal of		
Δ	AN Cerebrovascular Amyloid Protein", vol. 120, no. 3, pages 885-890  MASTERS, Colin L. et al. "Amyloid plaque core protein in Alzheimer disease and Down syndrome", Proc. Natl. Acad. Sci vol. 82, pages 4245-4249  1985					
А						
	DAVIES, L. et al. "A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: Prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques", Neurology, vol. 38, pages 1688-1693 1988					
Α	SOTO, Claudio et al. "Structural Determinants of the Alzheimer's Amyloid beta-Peptide", Journal of Neurochemistry, vol. pages 1191-1198 1994 SISODIA, Sangram S. et al. "Role of the beta-amyloid protein in Alzheimer's disease", FASEB J., vol. 9, pages 366-370 1995					
A						
Δ			vth factor potentiates the neurotoxicity vol. 87, pages 9020-9023	of Additional References sheet(s) attached		
				Date Considered		

Form PTO 1449	U.S. DEPARTMENT OF COMMERCE	ATTY DOCKET NO.	SERIAL NO.			
(Modified)	PATENT AND TRADEMARK OFFICE	263378US0PCT	10/519,680			
		APPLICANT				
LIST OF REFE	RENCES CITED BY APPLICANT	Claudio SOTO-J	ARA, et al.			
1		FILING DATE	GROUP			
		January 7, 2005				
	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)					
AT	SOTO, Claudio. "Plaque busters: stravol. 5, pages 343-350 1999	ategies to inhibit amyloid formation in Alzheimer	s disease", Molecular Medicine Today,			
AU	YANKNER, Bruce A. et al. "Neurotoxicity of a Fragment of the Amyloid Precursor Associated with Alzheimer's Disease", Science, vol. 245, pages 417-420 1989					
AV	ROHER, A.E. et al. "Beta-Amyloid from Alzheimer Disease Brains Inhibits Sprouting and Survival of Sympathetic Neurons", Biochemical and Biophysical Research Communications, vol. 174, no.2, pages 572-579 1991					
AW	KOWALL, Neil W. et al. "An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P", Proc.Natl. Acad. Sci., vol. 88, pages 7247-7251 1991					
AX	LEVY, Efrat et al. "Mutation of the Alzheimer's Disease Amyloid Gene in Hereditary Cerebral Hemorrhage, Dutch Type", Science, vol. 248, pages 1124-1126 1990					
AY	TEAHAN, O. et al. "White matter pathology in Alzheimer's disease and vascular dementia: quantification by amyloid-beta precursor protein immunocytochemistry", Neuropathology and Applied Neurobiology, vol. 28, page 168-170 2002					
AZ	WISNIEWSKI, Thomas et al. "Molecular Biology of Brain Aging and Neurodegenerative Disorders", Acta Neurobiol. Exp., vol. 56, pages 267-279 1996					
ААА	MAURY, C.P.J. "Biology of Disease: Molecular Pathogenesis of beta-Amyloidosis in Alzheimer's Disease and Other Cerebral Amyloidoses", Laboratory Investigation, vol. 72, no. 1, pages 4-16					
AAB	JORDAN, Barry D. "Chronic Traumatic Brain Injury Associated with Boxing", Seminars in Neurology, vol. 20, no. 2, pages 179-185 2000					
AAC	GRAHAM, D.I. et al. "Altered beta-APP Metabolism After Head Injury and its Relationship to the Aetiology of Alzheimer's Disease", Acta Neurochir., supp. Vol. 66, pages 96-102 1996					
AAD	KANG, Jie et al. "The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor", Nature, vol.					
AAE	TANZI, Rudolph E. et al. "Amyloid beta Protein Gene: cDNA, mRNA Distribution, and Genetic Linkage Near the Alzheimer					
AAF	ROBAKIS, Nikolaos K. et al. "Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the					
AAG	GOLDGABER, Dmitry et al. "Characterization and Chromosomal Localization of a cDNA Encoding Brain Amyloid of					
ААН	MANN, D.M.A. et al. "An Analysis of the Morphology of Senile Plaques in Down's Syndrome Patients of Different Ages Using					
AAI	RUMBLE, Baden et al. "Amyloid A4 Protein and its Precursor in Down's Syndrome and Alzheimer's Disease", The New England Journal of Medicine, vol. 320, no.22, pages 1446-1452					
LAA	MANN, D.M.A. "Alzheimer's disease and Down's syndrome", Histopathology, vol. 13, pages 125-137 1988					
Examiner	<b>.</b>	Date	Considered			
		t citation is in conformance with MPEP 609; Dra	w line through citation if not in			

Form PTO 1449	U.S. DEPARTMENT OF COMMERCE	ATTY DOCKET NO.	SERIAL NO.				
(Modified)	PATENT AND TRADEMARK OFFICE	263378US0PCT	10/519,680				
		APPLICANT					
LIST OF REFE	RENCES CITED BY APPLICANT	Claudio SOTO-JA	RA, et al.				
/		FILING DATE	GROUP				
		January 7, 2005					
	OTHER REFERENCES (	Including Author, Title, Date, Pertinent Pages,	etc.)				
SEUBERT, Peter et al. "Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids", Nature, vol							
AAK	AAK 359, pages 325-327 1992						
AAL	SHOJI, Mikio et al. "Production of the Alzheimer Amyloid beta Protein by Normal Proteolytic Processing", Science, vo AAL pages 126-129 1992						
ААМ	MORI, Hiroshi et al. "Mass Spectrometry of Purified Amyloid beta Protein in Alzheimer's Disease", The Journal of Biologic Chemistry, vol. 267, no. 24, pages 17082-17086						
AAN	MILLER, David L. et al. "Peptide Compositions of the Cerebrovascular and Senile Plaque Core Amyloid Deposits of AAN Alzheimer's Disease", Archives of Biochemistry and Biophysics, vol. 301, no.1, pages 41-52 1993						
AAO	THOMAS, Philip J. et al. "Defective protein folding as a basis of human disease", TIBS, vol. 20, pages 456-459						
AAP	SOTO, Claudio et al. "Alzheimer's and prion disease as disorders of protein conformation: implications for the design of novel therapeutic approaches", J. Mol. Med., vol. 77, pages 412-418						
AAQ	SERPELL, L.C. et al. "The molecular basis of amyloidosis", CMLS, vol. 53, pages 871-887  AAQ 1997						
AAR	SIPE, Jean D. "Amyloidosis", Annu. Rev. Biochem, vol. 61, pages 947-975 1992						
AAS	GHISO, Jorge et al. "Unifying Features of Systemic and Cerebral Amyloidosis", Molecular Neurobiology, vol. 8, pages 49-64 1994						
AAT	SOTO, Claudio et al. "Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides", The Lancet, vol. 355, pages 192-197 2000						
AAU	AAU SOTO, Claudio et al. "The alpha-Helical to beta-Strand Transition in the Amino-terminal Fragment of the Amyloid beta-Peptide Modulates Amyloid Formation", The Journal of Biological Chemistry, vol. 270, no.7, pages 3063-3067						
AAV	YANKNER, Bruce A. "Mechanisms of Neuronal Degeneration in Alzheimer's Disease", Neuron, vol. 16, pages 921-932 1996						
AAW	LEVINE, Harry III. "Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: Detection of amyloid aggregation in solution", Protein Science, vol. 2, pages 404-410 1993						
AAX	TRIGUERO, Domingo et al. "Capillary Depletion Method for Quantification of Blood-Brain Barrier Transport of Circulating Peptides and Plasma Proteins", Journal of Neurochemistry, vol. 54, pages 1882-1888						
AAY							
AAZ							
Examiner Date Considered							
	reference is considered, whether or no ot considered. Include copy of this form	citation is in conformance with MPEP 609; Draw with next communication to applicant.	line through citation if not in				